Metabolism Disorder TRIZ Cases

Modified GLP-1R agonist variant linked to FGF21 reduces gastrointestinal adverse effects while maintaining therapeutic efficacy for obesity treatment.

Crystalline insulin-conjugates exhibit glucose-responsive pharmacokinetics through high-affinity saccharide ligands.

Sodium 2,2-dimethylbutanoate converts toxic propionyl-CoA and methylmalonyl-CoA into less harmful substances via alternative metabolic pathways.

An islet-like organoid uses monSTIM1 to regulate insulin secretion via light irradiation.

Exosome-based compositions transfer differentiation factors to target cells.

Oral Type I interferons resist stomach acid degradation to inhibit Th17 activation, preventing systemic immunosuppression.

Chemical induction converts somatic cells to brown adipocytes, eliminating canceration risks from gene transfer.

Extraction isolates bromoform from algae into a water-soluble carrier, eliminating malodorous components that reduce feed palatability and extending shelf-life.

A dietary supplement combining propionyl L-carnitine and coenzyme Q10 to enhance skeletal muscle energy utilization.

Anti-MAdCAM directs anti-PD-1 agonists to pancreatic tissue, creating localized immune suppression that prevents systemic side effects.

Standardized olive fruit extract containing 15 to 20 mg daily hydroxytyrosol reduces body weight and visceral fat in overweight women.

Formic acid-producing bacterial strains lower blood triglyceride and cholesterol levels without the side effects of conventional anti-obesity medications.

Liposomal cannabidiol formulations enhance oral bioavailability and reduce required dosages for therapeutic applications.

Recombinant heparan N-sulfatase administered intrathecally targets the central nervous system to reduce glycosaminoglycan accumulation.

Anti-PDGF beta-receptor antibody reduces extracellular matrix accumulation by blocking Smad1-mediated signaling pathways.

Co-administering insulin and glucagon at specific molar ratios prevents hypoglycemia risk while maintaining glycemic control.

Incorporating crystalline calcium sulphate into food products binds dietary fats in the digestive system to reduce calorie intake.

Controlled particle size distribution in whey protein granules eliminates clumping to ensure high water solubility.

Attaching branched amino acid probes to exendin-4 peptides overcomes metabolic instability while preserving agonist activity.

Bivalent metal ions chelate methionine to raise solubility, reducing raw material costs compared to conventional high-mineral methods.

Co-expressing HB-EGF and ADAM12S converts white adipocytes to brown adipose tissue, addressing obesity by enhancing metabolic activity.

C5 ketone bodies increase blood ketone levels to treat mitochondrial dysfunction while improving mental and physical performance.

Engineered glycosylation acceptor sites in immunoglobulin variable domains ensure homogeneous product profiles and stable binding affinity.

A conjugated molecule merges GLP-1 agonism with NMDAR antagonism to suppress food intake.

Aspartic and glutamic acid extend insulin glargine stability at 30°C for 12 weeks.

Static settlement after heating separates impurities from the supernatant, yielding a tenfold increase in amylase inhibitory activity.

Sebelipase alfa hydrolyzes accumulated lipids in lysosomes, reversing Ishak fibrosis stages while minimizing patient administration burden.

Merging MC4r and GLP-1 agonists reduces side effects while improving glycemic control.

A sugar-responsive gel composition uses phenylboronic acid and hydroxyl monomers to enable controlled insulin release.

Encapsulated hydrogel microparticles deliver carbohydrates gradually, reducing excessive glycemic response while maintaining optimal absorption rates.

Lactobacillus microvesicles preserve beta cell function by reducing proinflammatory responses and preventing autoimmune destruction.

Modified urocortin-2 polypeptides extend half-life and preserve lean mass while treating diabetes.

Segmented incretin-insulin conjugates lower glucose and promote weight loss by targeting liver receptors, reducing hypoglycemia risk.

An anti-PSGL-1 antibody with an S228P mutation stabilizes IgG4 structure to selectively destroy activated T cells while reducing leukocyte recruitment.

Spermidine activates mitochondrial Complex I to increase respiratory activity, reducing reactive oxygen species accumulation while enhancing endurance.

PEG conjugation extends half-life to reduce dosing frequency while maintaining safe hypercalcemia levels.

Pemafibrate activates PPARα to lower triglycerides, addressing residual cardiovascular risk despite statin therapy.

Hepatic A20 overexpression normalizes blood glucose and increases glycogen storage without causing hypoglycemia.

Targeting COTL1 expression resolves the trade-off between symptom relief and fundamental cartilage repair in osteoarthritis treatment.

Organic solvent extract from tempeh-fungus-fermented soybean activates PPARα and PPARδ receptors to promote fatty acid metabolism.

Fatty acid modification extends protein half-life by increasing molecular weight and reducing renal clearance.

Low-temperature chemical crosslinking preserves protein activity while the biomaterial promotes bone tissue regeneration.

A diosmin hydrogen sulfate derivative regulates body weight imbalance through metabolic pathways.

Plasminogen administration lowers serum cholesterol and triglyceride levels while repairing vascular injuries caused by persistent lipid accumulation.

Fatty acid esters of hydroxy fatty acids protect pancreatic beta cells from apoptosis and stimulate insulin secretion.